LX2343

LX2343 (CAS No.: 333745-53-2) is a small-molecule inhibitor with dual activity against β-site amyloid precursor protein cleaving enzyme 1 (BACE1) and phosphoinositide 3-kinase (PI3K), positioning it as a multifunctional modulator in neurodegeneration research, particularly in Alzheimer’s disease. It exhibits inhibitory potency in the low micromolar range for both targets and functions as a non-ATP-competitive inhibitor of PI3K, while also suppressing BACE1-mediated amyloidogenic processing. Mechanistically, LX2343 reduces amyloid-β (Aβ) production and accumulation while simultaneously enhancing autophagic pathways, as evidenced by decreased phosphorylation of PI3K/Akt/mTOR signaling components and reduced levels of autophagy substrate markers, thereby promoting Aβ clearance. In cellular models, including HEK293 and CHO cells expressing amyloid precursor protein variants, LX2343 decreases Aβ40 and Aβ42 levels in a concentration-dependent manner and attenuates associated signaling events such as JNK activation and APP phosphorylation. In neuronal and glial systems, it further facilitates Aβ clearance, supporting its role in proteostasis regulation. In vivo, LX2343 has demonstrated efficacy in transgenic mouse models of Alzheimer’s disease, where it reduces amyloid burden in brain regions and improves cognitive performance in behavioral assays. This compound is therefore widely utilized as a research tool for studying amyloid metabolism, autophagy modulation, and PI3K-related signaling pathways, with experimental concentrations or dosing regimens varying according to specific study designs and objectives.